Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713233 | 0.83 | GPR119 (0.62) | GPR119GPR183KCNH2 | |
| SCHEMBL1713308 | 0.83 | GPR119 (0.47) | GPR119GPR183KCNH2 | |
| SCHEMBL1713507 | 0.79 | GPR119 (0.46) | GPR119GPR183ABCB1ABCC1ABCG2 | |
| SCHEMBL3218225 | 0.78 | GPR119 (0.47) | GPR119GPR183ABCB1ABCC1ABCG2 | |
| SCHEMBL3315647 | 0.78 | GPR119 (0.45) | GPR119GPR183KCNH2 | |
| SCHEMBL1625928 | 0.78 | HSD11B1 (0.44) | — | |
| SCHEMBL461992 | 0.77 | GPR119 (0.55) | GPR119GPR183ABCB1ABCC1ABCG2 | |
| SCHEMBL120996 | 0.77 | GPR119 (0.52) | GPR119GPR183ABCB1ABCC1ABCG2 | |
| SCHEMBL470560 | 0.77 | GPR119 (0.55) | GPR119GPR183ABCB1ABCC1ABCG2 | |
| SCHEMBL1713018 | 0.76 | GPR119 (0.47) | GPR119GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-2114935-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008081207-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885GPR183 45/4885ABCB1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.